Autopsy report · NCT05984784

A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)

“Cohort 1 was completed. Cohort 2 was cancelled because data from Cohort 1 provided sufficient information for further development decision. No safety concerns were noted.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 9 months before it stopped.
• 13 participants enrolled.
• Results were posted on the registry 1 year 6 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Inmagene LLC

Sponsor type

Industry

Conditions

Atopic Dermatitis; Moderate-to-severe Atopic Dermatitis; AD

Interventions

Placebo; IMG-007

Participants

13

Sites

12

Countries

Canada, United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.